IXICO PlC (AIM: IXI) Chief Commercial Officer, Lammert Albers joined Steve Darling from Proactive with news the company is to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease.
Albers telling Proactive "these services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development.”
Price: 90.4 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
The market report with Katie Pilbeam. FTSE 100 headed to the Christmas break in good cheer on the growing possibility that a Brexit deal will be announced today. The news overshadowed reports of another mutant coronavirus strain and helped London’s blue-chip index rise 19 to 6,515. Yes,...
